Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Aromatase inhibitors or tamoxifen Sponsors: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials
Conditions: Breast Cancer Interventions: Behavioral: Survey; Behavioral: mHealth app Sponsors: UNC Lineberger Comprehensive Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Prehabilitation Exercise Program in Breast Cancer: Effects on Quality of Life and Tumor Microenvironment (PEP_BC)
Conditions: Breast Cancer Interventions: Behavioral: Prehabilitation exercise program Sponsors: Institut Nacional d ' Educacio Fisica de Catalunya; ICFO - The Institute of Photonics Sciences; Hospital Clinic of Barcelona; Institut d ' Investigacions Biom èdiques August Pi i Sunyer; Universidad San Jorge Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging
Conditions: Breast Cancer Interventions: Diagnostic Test: 18F FDG PET/CT; Diagnostic Test: 68Ga DOTATATE PET/CT Sponsors: Celal Bayar University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide
Conditions: Stage IV Breast Cancer Interventions: Combination Product: Karanahan Sponsors: KARANAHAN Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Sacituzumab Govitecan Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population
Conditions: Breast Cancer Sponsors: Ain Shams University; British University In Egypt Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma
Conditions: Invasive Breast Cancer Interventions: Other: no intervention Sponsors: Marwa Mahmoud Hassan; Qena Oncology Center Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Other: Pre-treatment biopsy Sponsors: Center Eugene Marquis Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Conditions: Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer Interventions: Drug: INT230-6; Other: neoadjuvant immuno-chemotherapy Sponsors: Swiss Group for Clinical Cancer Research Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
Conditions: Advanced Breast Cancer Interventions: Drug: SYHX2011 Sponsors: CSPC Ouyi Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Conditions: Triple-negative Breast Cancer Interventions: Drug: Inosine; Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
IV Dexmedetomidine vs Oral Gabapentin and Their Combination for Postoperative Analgesia in Cancer Patients Undergoing Modified Radical Mastectomy
Conditions: Breast Cancer; Pain, Postoperative; Pain, Acute Interventions: Drug: Dexmedetomidine Hydrochloride 0.5 MG/ML; Drug: Gabapentin Sponsors: National Cancer Institute, Egypt Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
Conditions: Triple Negative Breast Cancer Interventions: Drug: Pembrolizumab; Drug: INBRX-106 Sponsors: Providence Health& Services; Inhibrx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Conditions: Triple-negative Breast Cancer Interventions: Drug: Quercetin; Drug: Dasatinib; Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
